Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01678560 · ClinicalTrials.gov registry record · NA

Remote Monitoring in Obstructive Sleep Apnea

A NA study, sponsored by VA Connecticut Healthcare System.

Terminated
Registry status
NA
Development phase
52
Enrollment target

NCT01678560: Clinical Trial NA study, sponsored by VA Connecticut Healthcare System.

NCT01678560 is a NA study that was terminated before completion, run by VA Connecticut Healthcare System. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01678560, a NA study, was terminated before completion, sponsored by VA Connecticut Healthcare System.

TERMINATED
Registry status
NA
Development phase
52 participants
Enrollment target

Study Summary

Obstructive sleep apnea (OSA) among Veterans is a condition that imparts a great burden to the patient in terms of serious co-morbidities and results in a great cost to the VA Health Care System to treat the co-morbidities, which include heart disease, stroke and neuropsychiatric disorders. Positive airway pressure (PAP) is used to treat sleep apnea and studies have shown a poor adherence to treatment. The investigators hypothesize that using wireless technology will lead to early detection of problems of treatment use and will translate into early remedial action which will improve the use and effectiveness of treatment. The investigators will compare two methods. Usual care involves downloading data from PAP machines at designated 3-month intervals, requiring a face-to-face clinician visit. Wireless care involved more frequent monitoring and intervention in the event of anomalies in treatment use or effectiveness.

Primary Outcome

Positive Airway Pressure Treatment Adherence defined as mean PAP use being \> 4 hours per night for greater than 70% of nights.

Interventions

  • DEVICE Monitoring every 3 months by face-to-face visits
  • DEVICE Frequent remote monitoring

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2014-01
Est. Completion 2016-12
Phase NA
VA Connecticut Healthcare System

26 total trials

Why NCT01678560 stopped before completion

NCT01678560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Monitoring every 3 months by face-to-face visits is the first listed.

NCT01678560 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01678560 about?

NCT01678560 is a clinical study titled "Remote Monitoring in Obstructive Sleep Apnea". Obstructive sleep apnea (OSA) among Veterans is a condition that imparts a great burden to the patient in terms of serious co-morbidities and results in a great cost to the VA Health Care System to treat the co-morbidities, which include heart disease, stroke and neuropsychiatric disorders. Positive...

What is the current status of trial NCT01678560?

This trial is currently terminated. It is a NA study. The enrollment target is 52 participants. The study started on 2014-01. Estimated completion is 2016-12.

What interventions are being tested in trial NCT01678560?

The interventions under investigation include: Monitoring every 3 months by face-to-face visits (DEVICE), Frequent remote monitoring (DEVICE).

Who is sponsoring clinical trial NCT01678560?

This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01678560's enrollment target sits among peer trials

52 1272nd of 2000 higher than 722 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01678560, the US trial registry maintained by the National Library of Medicine. NCT01678560 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.